A Fujifilm Biotechnologies’ commercial-scale cell culture manufacturing facility has been selected for the FDA’s PreCheck Pilot Program, the company announced. The CDMO’s Holly Springs, North Carolina, facility was selected as one of seven participants in the program designed to strengthen United States pharmaceutical manufacturing capabilities and accelerate patient access to critical medicines. “We are honored…
Fujifilm Biotechnologies expands in U.K.
Fujifilm Biotechnologies recently celebrated the grand opening of its expanded biopharmaceutical CDMO facility in Teesside, U.K. In a Feb. 11 news release, the company said the expansion introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L. The goal is to provide small- and mid-scale antibody manufacturing, and there’s…
Fujifilm Biotechnologies opens $3.2B manufacturing site in North Carolina
Fujifilm Biotechnologies recently announced it opened a $3.2 billion commercial-scale cell culture manufacturing site in Holly Springs, N.C., with eight 20,000-liter bioreactors and plans to double capacity. The facility is one of the largest commercial cell culture sites in North America, the company said. Phase one spans drug substance and drug product manufacturing, with finished…